Products Collaborations Better Planet Company News Join Us Lines of Business Fast Growing Sales Network Alvogen has commercial operations in more than 30 countries, with manufacturing and R&D capabilities in the U.S., South-Korea and Romania. Alvogen's lines of business include: product development, contract manufacturing (CMO), contract research (CRO) and sales of generic medicines (Gx and Hx), biosimilars and OTC’s. Alvogen's product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology in addition to a fast growing portfolio of biosimilars and OTC products. Product formulations manufactured and sold by Alvogen include solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables. Contact regional offices for information on product offering in your country. The US market continues to be the most important market for Alvogen, contributing approximately half of the group's revenues. Other key markets include: Hungary, Romania, South-Korea, Bulgaria, Serbia, Russia, Ukraine, China, Thailand and Taiwan. WORLDWIDE OFFICES Generics Exceptional teams with proven track records are building the next generation generics company. An experienced team of professionals from the generic industry with proven track records has built a strong profitable base and infrastructure for generic business in America, CEE and APAC. Teams in more than 30 countries and a world class regulatory team Based in the U.S., we have one of the best first-to-file teams in the industry with multiple successful filings to their credit Concentration on real Para IV FTF opportunities for both IR and ER as early as late phase 3 Product formulations manufactured and sold by Alvogen include solid oral dosage, soft gelatin capsules, modified release tablets, transdermals, creams, ointments and injectables Niche products with limited competition: (i.e.) Patches, controlled substances, clinical end point studies, toxic substances and products with safety monitoring (REMS) Contract Manufacturing A long tradition of contract manufacturing for both originators as well as companies operating in the generic industry With its 125-year history, Norwich provides contract manufacturing and product development services to third party customers Norwich has a proven record of successfully meeting compliance requirements for regulatory agencies worldwide, including FDA, EMA and ANVISA NPI capabilities finished dose form manufacturing and packaging include tablets, capsules, liquids, semi-solids, and sponges NPI also offers regulatory affairs/ quality assurance services, analytical, micro and stability labs, drug enforcement, agency controlled substance licenses (CII-CV), containment suite for intermediate potency, compounds and area for potent compounds Contract Research Our experienced CRO team offers fully accredited clinical and pharmacovigilance service to third party customers. Norwich Clinical Services (NCS) is a part of Alvogen’s third party services Located in Bangalore, India with an exceptional team of experienced scientists and managers. NCS provides bioequivalence, bio-analytical and clinical services as well as pharmacovigilance services. The Norwich Clinical Services management team has: More than a decade’s experience in setting up and managing clinical trial business Conducted about 2000 biostudies and numerous clinical trials More than 40 successful regulatory inspections including US-FDA, EU OTC Tailor-made portfolio for each market based on local expertise and regional characteristics Alvogen has hundreds of products in its growing OTC portfolio that promote a healthy lifestyle and offer innovative solutions to everyday problems The products span four major categories: OTC medicines, food supplements, medical devices and cosmetics Most of the products in the Alvogen OTC portfolio offer unique solutions, using patented technology with clinically proven efficacy Other OTC products are commonly found in regular households, such as painkillers, anti-histamines and ointments Our OTC strategy centers around comprehensive solutions based on unique target market segmentation and value added properties such as taste, delivery form, or ingredient composition Biosimilars Strong commitment for success in the fast paced exciting new field of biosimilars Through Alvogen’s sales network in 30 countries, the company is promoting and distributing a range of biosimilars in partnerships with third parties Alvogen’s sister company Alvotech is investing into the development of biosimilar monoclonal antibodies for key biologic molecules. The Alvotech – Alvogen alliance will strengthen Alvogen’s position as a key worldwide biosimilar player, promoting and distributing a variety of biosimilar products for many indications across several therapeutic areas. Find a Supplier in Your Country Alvogen has commercial operations in more than 30 countries, with manufacturing and R&D capabilities in the U.S. and Korea. North America is Alvogen’s largest market with approximately half of the group’s sales. Other key markets include Hungary, Romania, South Korea, Bulgaria, Serbia, Russia, Ukraine, China, Thailand and Taiwan. WORLDWIDE OFFICES Alvogen on Twitter info@alvogen.com Terms of Use Privacy Policy © 2013 Alvogen. All rights reserved